How to fight pertussis?
- PMID: 24757515
- PMCID: PMC3967663
- DOI: 10.1177/2051013613481348
How to fight pertussis?
Abstract
Universal pertussis vaccination has successfully decreased pertussis mortality and morbidity in childhood. However, despite intensive vaccination of young children, pertussis remains a major public health problem in both developing and industrialized regions. Recent epidemics in California and Australia demonstrated that the agent of the disease is still circulating. They also revealed several aspects that must not be neglected concerning vaccine-preventable diseases. Indeed, pertussis is one of the oldest vaccine-preventable bacterial diseases, so can provide a good illustration of all of the aspects associated with the need for surveillance after the introduction of vaccination. (i) The type of vaccine: two types of pertussis vaccine, whole cell and acellular, inducing different types of immunity are now used around the world. (ii) The vaccine strategy, the vaccine coverage and the duration of vaccine immunity: pertussis epidemics provide evidence that 90% of the infants must be vaccinated, vaccination must be sufficiently early and both vaccine-induced immunity and natural infection-induced immunity to pertussis wane with time indicating that pertussis is not only a pediatric disease. (iii) The agents of the disease, Bordetella pertussis and Bordetella parapertussis: the intensive vaccination of young infants modified the herd immunity, controlled bacteria similar to the vaccine strains but not all, revealing polymorphism of the agents of the disease evidencing the importance of continuing their isolation and their surveillance as well as monitoring their antibiotic resistance. (iv) The diagnosis of the disease: the epidemics showed the importance of specific diagnostic techniques that are easy to use by medical laboratories and the availability of the reagents required. (v) Communication with the public, the health authorities and the health providers: any changes of vaccine type, vaccine strategy, characteristics of the disease, and biological diagnosis must be associated with appropriate communication with the public and training of healthcare workers. Currently, herd immunity needs to be increased by introducing vaccine boosters for adolescents and adults to protect the most vulnerable group: unvaccinated newborns.
Keywords: Bordetella species; diagnosis; pertussis vaccines; surveillance.
Conflict of interest statement
Similar articles
-
[Whooping cough from infants to adults].Bull Acad Natl Med. 2008 Oct;192(7):1437-49; discussion 1449-52. Bull Acad Natl Med. 2008. PMID: 19445367 Review. French.
-
[Impact of vaccination on the infectious diseases epidemiology: example of pertussis].Med Sci (Paris). 2007 Apr;23(4):399-403. doi: 10.1051/medsci/2007234399. Med Sci (Paris). 2007. PMID: 17433230 Review. French.
-
Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.Pediatrics. 2001 Nov;108(5):E81. doi: 10.1542/peds.108.5.e81. Pediatrics. 2001. PMID: 11694665 Clinical Trial.
-
Re-emergence of pertussis: what are the solutions?Expert Rev Vaccines. 2012 Nov;11(11):1331-46. doi: 10.1586/erv.12.118. Expert Rev Vaccines. 2012. PMID: 23249233 Review.
-
Bordetella pertussis: why is it still circulating?J Infect. 2014 Jan;68 Suppl 1:S119-24. doi: 10.1016/j.jinf.2013.09.022. Epub 2013 Oct 5. J Infect. 2014. PMID: 24103807 Review.
Cited by
-
Study on Toxicity Reduction and Potency Induction in Whole-cell Pertussis Vaccine by Developing a New Optimal Inactivation Condition Processed on Bordetella pertussis.Jundishapur J Microbiol. 2016 Jul 9;9(7):e34153. doi: 10.5812/jjm.34153. eCollection 2016 Jul. Jundishapur J Microbiol. 2016. PMID: 27679704 Free PMC article.
-
The role of Toll-like receptor 4 polymorphisms in vaccine immune response.Pharmacogenomics J. 2016 Feb;16(1):96-101. doi: 10.1038/tpj.2015.21. Epub 2015 Mar 31. Pharmacogenomics J. 2016. PMID: 25823688 Review.
-
Bordetella pertussis: an underreported pathogen in pediatric respiratory infections, a prospective cohort study.BMC Infect Dis. 2014 Sep 30;14:526. doi: 10.1186/1471-2334-14-526. BMC Infect Dis. 2014. PMID: 25267437 Free PMC article.
-
Pertussis.Hum Vaccin Immunother. 2015;11(1):108-17. doi: 10.4161/hv.34364. Epub 2014 Nov 1. Hum Vaccin Immunother. 2015. PMID: 25483523 Free PMC article. Review.
References
-
- Advisory Committee on Immunization Practices (ACIP) (2011) Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months. MMWR 60: 1424–1426 - PubMed
-
- Baron S., Njamkepo E., Grimprel E., Begue P., Desenclos J., et al. (1998) Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediat Inf Dis J 17: 412–418 - PubMed
-
- Bass J., Stephenson S. (1987) The return of pertussis. Pediatr Infect Dis J 6: 141–144 - PubMed
-
- Beytout J., Launay O., Guiso N., Fiquet A., Baudin M., Richard P., et al. (2009) Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin 5: 315–321 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources